A Study to Compare and Evaluate the Safety, Tolerability and Pharmacokinetics Between DA-5223 and DA-5223-R in Healthy Adult Subjects
PHASE1CompletedINTERVENTIONAL
Enrollment
38
Participants
Timeline
Start Date
July 4, 2025
Primary Completion Date
July 17, 2025
Study Completion Date
July 17, 2025
Conditions
Healthy Adult
Interventions
DRUG
DA-5223-R
once a day
DRUG
DA-5223
once a day
Trial Locations (1)
13520
CHA Global Clinical Trials Center, Seongnam-si
All Listed Sponsors
lead
Dong-A ST Co., Ltd.
INDUSTRY
NCT07007533 - A Study to Compare and Evaluate the Safety, Tolerability and Pharmacokinetics Between DA-5223 and DA-5223-R in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter